The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | FiTNEss trial: frailty-adjusted therapy in transplant-ineligible newly diagnosed myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, provides a brief update on the FiTNEss trial (NCT03720041), a Phase III trial comparing standard and frailty-adjusted induction therapy with ixazomib, lenalidomide, and dexamethasone, plus lenalidomide maintenance to lenalidomide plus ixazomib in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The FITNESS trial, which is a newly diagnosed transplant-ineligible myeloma trial, was reported at ASH by Gordon Cook. And this is the first trial to look at a frailty score-based adaptation right at the outset for newly diagnosed myeloma patients. What Gordon Cook presented was the first cut of data, but it’s already shown in a very long follow-up, potentially a frailty score-based adjustment of therapy right at the outset is beneficial for patients...
The FITNESS trial, which is a newly diagnosed transplant-ineligible myeloma trial, was reported at ASH by Gordon Cook. And this is the first trial to look at a frailty score-based adaptation right at the outset for newly diagnosed myeloma patients. What Gordon Cook presented was the first cut of data, but it’s already shown in a very long follow-up, potentially a frailty score-based adjustment of therapy right at the outset is beneficial for patients. So we’re waiting for further data in this clinical trial. And this again will have a significant change to our clinical care because currently we’re not routinely doing frailty scoring for all patients. So clearly this would be a major change for us in our ability to give care for patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
GSK: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Adaptive Biotech: Consultancy, Speakers Bureau; Johnson and Johnson: Consultancy, Speakers Bureau; Menarini Stemline: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Recordati rare Disease: Consultancy, Speakers Bureau.
